Spero Therapeutics, Inc.
SPRO
$0.60
$0.02253.90%
| Weiss Ratings | SPRO - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Very Weak | |||
| Risk Index | Weak | |||
| Risk Grade | D- | |||
| Reward Grade | E+ | |||
| Rating Factors | SPRO - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | -- | |||
| Growth Index | Weak | |||
| Efficiency Index | Very Weak | |||
| Solvency Index | Good | |||
| Total Return Index | Very Weak | |||
| Volatility Index | Weak | |||
| Beta / Standard Deviation | SPRO - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | 1.04 | |||
| Price History | SPRO - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | -15.01% | |||
| 30-Day Total Return | -22.64% | |||
| 60-Day Total Return | -33.13% | |||
| 90-Day Total Return | -47.37% | |||
| Year to Date Total Return | -44.44% | |||
| 1-Year Total Return | -64.91% | |||
| 2-Year Total Return | -62.96% | |||
| 3-Year Total Return | -91.16% | |||
| 5-Year Total Return | -92.36% | |||
| 52-Week High % Change | -67.00% | |||
| 52-Week Low % Change | 14.31% | |||
| Price | SPRO - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $1.75 | |||
| 52-Week Low Price | $0.51 | |||
| 52-Week Low Price (Date) | Apr 09, 2025 | |||
| 52-Week High Price (Date) | Apr 11, 2024 | |||
| Valuation | SPRO - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 32.28M | |||
| Enterprise Value | -16.31M | |||
| Price/Earnings (TTM) | -- | |||
| Earnings Per Share (TTM) | -1.27 | |||
| Earnings Per Share Growth | -400.33% | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | 0.66 | |||
| Price/Book (Q) | 0.68 | |||
| Enterprise Value/Revenue (TTM) | -0.34 | |||
| Price | $0.60 | |||
| Enterprise Value/EBITDA (TTM) | 0.23 | |||
| Enterprise Value/EBIT | 0.23 | |||
| Market Cap Category | Nano Cap | |||
| Dividends and Shares | SPRO - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 54.54M | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -- | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | SPRO - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | (857) 242-1600 | |||
| Address | 675 Massachusetts Avenue Cambridge, MA 02139 | |||
| Website | sperotherapeutics.com | |||
| Country | United States | |||
| Year Founded | 2013 | |||
| Profitability | SPRO - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | -151.08% | |||
| Profit Margin | -142.91% | |||
| Management Effectiveness | SPRO - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | -30.93% | |||
| Return on Equity | -- | |||
| Income Statement | SPRO - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | 47.98M | |||
| Total Revenue (TTM) | 47.98M | |||
| Revenue Per Share | $0.88 | |||
| Gross Profit (TTM) | -71.25M | |||
| EBITDA (TTM) | -72.39M | |||
| EBIT (TTM) | -72.48M | |||
| Net Income (TTM) | -68.57M | |||
| Net Income Avl. to Common (TTM) | -68.57M | |||
| Total Revenue Growth (Q YOY) | -79.54% | |||
| Earnings Growth (Q YOY) | -140.80% | |||
| EPS Diluted (TTM) | -1.27 | |||
| EPS Diluted Growth (Q YOY) | -139.87% | |||
| Balance Sheet | SPRO - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 52.89M | |||
| Cash Per Share (Q) | $0.97 | |||
| Total Current Assets (Q) | 107.28M | |||
| Total Preferred Equity (Q) | -- | |||
| Total Equity (Q) | 46.12M | |||
| Current Ratio (Q) | 2.186 | |||
| Book Value Per Share (Q) | $0.84 | |||
| Total Assets (Q) | 110.54M | |||
| Total Current Liabilities (Q) | 49.07M | |||
| Total Debt (Q) | 4.30M | |||
| Total Liabilities (Q) | 64.42M | |||
| Total Common Equity (Q) | 46.12M | |||
| Cash Flow | SPRO - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | -- | |||
| Cash from Financing (TTM) | -- | |||
| Net Change in Cash (TTM) | -23.44M | |||
| Levered Free Cash Flow (TTM) | -43.53M | |||
| Cash from Operations (TTM) | -23.44M | |||
